The emergence of multiple carbapenemases and the consequent multi drug resistance in bacteria 14 constitute a grave concern in the management of critical care patients and also in community 15 acquired infections. Detection of carbapenamase activity helps to understand the possible 16 mechanism(s) of carbapenem resistance in the microorganism. Identification of carbapenemases 17 is currently being done by various phenotypic methods and molecular methods. However, 18 innovative biochemical and spectrophotometric methods are desirable as they will be easy to 19 perform, affordable and rapid. Recently a novel chromogenic method called CarbaNP test was 20 introduced to screen for carbapenemases in clinical isolates of gram negative pathogens. We 21 adopted this assay: (i) to detect the total carbapenemase activity (ii) to measure the relative rates 22 of hydrolysis of imipenem by class A, B and D carbapenemases with inhibitors (iii) to confirm 23 the genotype by PCR and (iv)for direct differential detection of various carbapenemases in 24 uncultured clinical sample like tracheal aspirate. The study included 75 culture isolates and 153 25 purulent tracheal aspirates. All isolates were screened by our optimized protocol and also 26 genotyped by PCR. This adopted assay showed good sensitivity and correlation with 27 conventional phenotyping and genotyping. Our protocol offers the fastest way to identify the 28 pathogen by PCR but also its carbapenemase profile directly from uncultured clinical samples in 29 2 less than 4h. Our protocol is currently being validated on other types of clinical specimens in our 30 laboratory.
Preparation of genomic DNA of A. baumannii:
Pure single colony of each isolate was 90 suspended in 100 μl of TEX buffer (10 mM Tris-HCl pH 8.5, 1 mM EDTA, 1% (w/v) Triton X-91 100). The suspension was vortexed to achieve a uniform suspension and centrifuged. The pellet 92 was subjected to another wash in TEX buffer. Finally the pellet was resuspended in 100 µl of 93 TEX buffer and lysed by heating in a dry bath at 95˚C for 15min [18] . The lysate was used as the 94 DNA template for PCR amplifications. All isolates were screened by PCR using primers 95 designed for the carbapenemase genes-bla KPC , bla NDM-1 , bla OXA-23-like , bla OXA-51-like and the 96 species marker (Ab-ITS) of A. baumannii as described in " ZnSO4 and 30 μL of phenol red (pH8.5) were added to the wells and incubated at 37 0 C up to 2 h.
127
The carbapenemase activity was identified by a change in color of phenol red to yellow. The 128 absorbance of the solution in the microtiter wells was measured at different time intervals (T 0 ,
129
T 15 , T 30 , T 60 and T 120 min) at 546 nm.
130

RESULTS
131
Carbapenemase detection:
132
To extend the chromogenic assay protocol to uncultured clinical samples: first we optimized the 133 assay on a few culture isolates (n= 75) of A. baumannii. These isolates were screened for species 134 specific marker Ab-ITS (16S-23S rRNA spacer region) and carbapenemase genes through PCR.
135
The distribution of carbapenemase genes among these culture isolates of A. baumannii were as 
244
We introduced certain modifications to Nordmann's protocol to make it more user friendly, to 245 reduce the quantity of cells required and to apply it directly to uncultured tracheal aspirates. format can be easily adopted for a high throughput screening of carbapenemases in clinical 264 samples or isolates. We hope it will become a valuable and useful tool in clinical microbiology 265 screening and to study the epidemiology of carbapenemase producers [12] .
266
Conclusion 267
We propose the following algorithm to screen uncultured clinical samples directly for 268 carbapenemase activity: 
